Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus

Diseases of the Esophagus

Volumn 16, Issue 3, 2003, Pages 193-198

  Yeh, R W ^a,b   Gerson, L B ^a,b   Triadafilopoulos, George ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Esomeprazole; Gastroesophageal reflux disease (GERD); pH monitoring; Proton pump inhibitor therapy

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER PREVENTION; CHEMOPROPHYLAXIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE CONTROL; DOSE CALCULATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH ACID; STOMACH PH; TREATMENT FAILURE;

BARRETT ESOPHAGUS; ESOPHAGUS; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; STOMACH;

EID: 0242438093     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.2003.00327.x     Document Type: Article

References (24)

1. Fitzgerald R C, Thiadafilopouloso G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis Sci 1998; 16: 63-80.
2. Koop H. Reflux disease and Barrett's esophagus. Endoscopy 2000; 32: 101-7.
3. Spechler S J. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992; 51: 24-9.
4. Orlando R C. The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997; 92: 3S-7S.
5. Altorki N K, Oliveria S, Schrump D S. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol 1997; 13: 270-80.
6. Niemantsverdriet E, Timmer R, Breumelhof R, Smouth A J P M. The roles of excessive gastro-oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's esophagus. Eur J Gastroenterol Hepatol 1997; 9: 515-19.
7. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-16.
8. Katzka D A, Castell D O. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91.
9. Fass R, Sampliner R E, Malagon I B et al. Failure of oesophageal acid control in candidates for Barrett's esophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597-602.
10. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
11. Kahrilas P J, Falk G W, Johnson D A et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-58.
12. Richter J E, Kahrilas P J, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
13. Jamieson J R, Stein HJ, DeMeester T R, et al. Ambulatory 24-h esophageal pH monitoring. Normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 1992; 87: 1102-11.
14. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 1999; 340: 825-31.
15. Valanovich V J. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg 1998; 2: 141-5.
16. Peghini P L, Katz P O, Castell D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
17. Katz P O. Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001; 33: 107-13.
18. Peghini P L, Katz P O, Bracy N A, Castell D O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
19. Katz P O, Anderson C, Khoury R, Castell D O. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
20. Fouad Y M, Katz P O, Castell D O. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13: 1467-71.
21. Triadafilopoulos G. Proton pump inhibitors for Barrett's oesophagus. Gut 2000; 46: 144-6.
22. Ouatu-Lascar R, Fitzgerald R, Triadafilopoulos G. Differentiation, and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335.
23. Fitzgerald R C, Omary M B, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. J Clin Invest 1996; 98: 2120-8.
24. Fennerty M B, Triadafilopoulos G. Barrett's-related esophageal adenocarcinoma. Is chemoprevention a potential option? Am J Gastro 2001; 96: 2302-5.